Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: The Story Behind The Pharmaprojects’ Pharma R&D Annual Review 2021

Executive Summary

In this one-off podcast, hear in the inside story of how the Pharmaprojects’ Pharma R&D Annual Review 2021 is put together, its history and the trends it has revealed in R&D over the years.

You may also be interested in...



The 2021 Worldwide Pharma And Biotech R&D Scene

INFOGRAPHIC: A snapshot of the industry in key performance indicators surrounding R&D taken in early 2021.

COVID-19 Made Its Mark On the R&D Pipeline And Novel Drug Launches In 2020

A new analysis reveals the impact of the coronavirus pandemic on pharma R&D in 2020 in two quarters: the total size of the pipeline and in the number of novel products launched in their first markets.

Worldwide Novel Drug Launches Soared Amid Pandemic

The number of novel products launched in their first markets in 2020 hit record heights in spite of – and in part buoyed by – the pandemic, with an exceptional year for infectious diseases therapeutics and vaccines.

Related Content

Topics

UsernamePublicRestriction

Register

SC144331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel